v3.26.1
Agreements with Royalty Pharma - Additional Information (Detail) - USD ($)
$ in Thousands
3 Months Ended
Jan. 07, 2022
Mar. 31, 2026
Mar. 31, 2025
Jun. 30, 2024
Dec. 31, 2025
Dec. 31, 2024
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Arrangement consideration of debt transaction $ 150,000          
Liabilities   $ 2,100,046     $ 2,084,162  
RP OM Loan Agreement [Member]            
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Change in fair value of liabilities   1,800 $ (3,600)      
RP OM Loan Agreement And RP Ulacamten RPA [Member]            
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Change in fair value of liabilities   $ 1,600 $ 3,900      
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]   Liabilities, Fair Value Adjustment        
RP OM Loan Agreement And RP Ulacamten RPA [Member] | Maximum [Member]            
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Percentage of discount rates for fair values of derivative liabilities   17.00% 18.00%      
RP OM Loan Agreement And RP Ulacamten RPA [Member] | Minimum [Member]            
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Percentage of discount rates for fair values of derivative liabilities   12.00% 12.00%      
RP Multi Tranche Loan [Member]            
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Additional embedded derivatives recognized   $ 29,600 $ 11,700   $ 31,100 $ 11,300
Percentage of probability of default of derivative liabilities   10.00%        
RP Multi Tranche Loan [Member] | Maximum [Member]            
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Percentage of discount rates for fair values of derivative liabilities   13.00% 14.00%      
RP Multi Tranche Loan [Member] | Minimum [Member]            
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Percentage of discount rates for fair values of derivative liabilities   12.00% 12.00%      
2022 Royalty Pharma Transactions [Member]            
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Milestone payment 50,000          
2022 Royalty Pharma Transactions [Member] | RP Aficamten RPA, RPI ICAV [Member]            
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Upfront payment 50,000          
Imputed rate of interest on unamortized portion of liability   26.00% 23.50%      
2022 Royalty Pharma Transactions [Member] | RP Multi Tranche Loan [Member] | Term Loan Tranche 1 Tranche 4 Tranche 5 and Tranche 6 [Member]            
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Estimated fair value of long term debt   $ 277,300        
2024 RPI Transactions [Member]            
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Additional carrying value       $ 33,300    
Royalty Purchase Finance Trust Agreement [Member] | RP OM RPA [Member]            
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Imputed rate of interest on unamortized portion of liability   0.00% 0.10%      
Non-cash interest expense recognized   $ 92,300        
CRL Option [Member] | RP Multi Tranche Loan [Member] | Term Loan Tranche 7 [Member]            
Liabilities Related to Revenue Participation Right Purchase Agreements [Line Items]            
Term loan, maximum borrowing capacity $ 175,000